111
Participants
Start Date
October 9, 2015
Primary Completion Date
June 20, 2016
Study Completion Date
June 21, 2016
FF
FF will be provided as a dry powder inhaler with 30 doses per device, each containing 50 mcg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
Placebo
Placebo will be provided as dry powder inhaler with 30 doses per device, each containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
Montelukast
Montelukast will be provided as 4 mg and 5 mg chewable tablets.
Albuterol/Salbutamol
Albuterol/Salbutamol will be provided as inhalation aerosol.
GSK Investigational Site, Middelburg
GSK Investigational Site, Panorama
GSK Investigational Site, Bellville
GSK Investigational Site, Raleigh
GSK Investigational Site, Orangeburg
GSK Investigational Site, Homestead
GSK Investigational Site, Miami
GSK Investigational Site, Miami
GSK Investigational Site, Miami
GSK Investigational Site, Little Rock
GSK Investigational Site, Oklahoma City
GSK Investigational Site, Oklahoma City
GSK Investigational Site, Houston
GSK Investigational Site, Alhambra
GSK Investigational Site, Costa Mesa
GSK Investigational Site, Huntington Beach
GSK Investigational Site, Newport Beach
Lead Sponsor
GlaxoSmithKline
INDUSTRY